Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) Equity Average: 2021-2025

Historic Equity Average for Legend Biotech (LEGN) over the last 4 years, with Sep 2025 value amounting to $1.0 billion.

  • Legend Biotech's Equity Average fell 10.04% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 10.04%. This contributed to the annual value of $1.1 billion for FY2024, which is 14.84% up from last year.
  • As of Q3 2025, Legend Biotech's Equity Average stood at $1.0 billion, which was down 0.32% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Equity Average ranged from a high of $1.4 billion in Q3 2023 and a low of $170.1 million during Q2 2021.
  • Moreover, its 3-year median value for Equity Average was $1.1 billion (2024), whereas its average is $1.1 billion.
  • In the last 5 years, Legend Biotech's Equity Average spiked by 152.03% in 2022 and then fell by 17.17% in 2024.
  • Quarterly analysis of 5 years shows Legend Biotech's Equity Average stood at $495.9 million in 2021, then soared by 152.03% to $753.6 million in 2022, then dropped by 7.27% to $1.3 billion in 2023, then declined by 16.76% to $1.1 billion in 2024, then dropped by 10.04% to $1.0 billion in 2025.
  • Its Equity Average was $1.0 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.0 billion in Q1 2025.